Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

22.88 -0.49 (-2.10%)
Delayed Quote Updated: 11:42 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit ↗
uniQure (NASDAQ:QURE) reported updated Phase I/II data for its investigational Huntington’s disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose... 
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
UniQure (NASDAQ:QURE) Rises on Pipeline Progress Despite Wider Q2 Loss ↗
Via Chartmill
uniQure (NASDAQ:QURE) Stock Plummets 40% Despite Earnings Beat on FDA Setback for AMT-130 ↗
Via Chartmill
Topics Earnings
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
uniQure (QURE) Q2 2026 Earnings Call Transcript ↗
Gene therapy biotech secures FDA alignment for Huntington's disease BLA submission. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure... 
Via Benzinga
News headline image
uniQure Q2 Earnings Call Highlights ↗
uniQure (NASDAQ:QURE) said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease,... 
Via MarketBeat
Topics Earnings
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
Top movers in Wednesday's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗
Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease... 
Via Stocktwits
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure. 
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
Via Stocktwits
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Biotech Stock QURE Once Tagged ‘Failed Product’ — CEO Sold Shares Days Before Rally ↗
On Friday, the trading volume for uniQure increased from its 2 million shares to roughly 17 million. 
Via Stocktwits
Here are the top movers in Friday's session. ↗
Via Chartmill
News headline image
These Analysts Cut Their Forecasts On uniQure Following Q4 Results ↗
uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%. 
Via Benzinga
Iran, Dip-Buyers & a Rare Buffett Stumble: Wall Street Shakes Off Its Worst Fears ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
uniQure (QURE) Q4 2025 Earnings Call Transcript ↗
uniQure (QURE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
Why Did QURE Stock Almost Halve Pre-Market Today? ↗
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130. 
Via Stocktwits
News headline image
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? ↗
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121. 
Via Stocktwits
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.